Mylan Launches Generic Actonel

Mylan announced that the FDA has granted final approval for its Abbreviated New Drug Application (ANDA) for Risedronate Sodium Tablets, the generic version of Warner Chilcott’s Actonel.

Actonel is a bisphosphonate indicated for the treatment and prevention of osteoporosis in postmenopausal women. Actonel has an affinity for hydroxyapatite crystals in bone and acts as an antiresoprtive agent. At the cellular level, Actonel inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption.

RELATED: Osteoporosis Treatments

Risedronate Tablets are available in a 150mg strength and shipment has begun for this product.

For more information call (800) RX-MYLAN or visit